Seminars in Oncology
Volume 31, Issue 4 , Pages 554-565, August 2004

Treatment of localized esophageal cancer

  • Baruch Brenner

      Affiliations

    • Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tiqva and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationAddress reprint requests to Baruch Brenner, MD, Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel
  • ,
  • David H. Ilson

      Affiliations

    • Gastrointestinal Oncology Service, Department of Medicine, and the Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
  • ,
  • Bruce D. Minsky

      Affiliations

    • Gastrointestinal Oncology Service, Department of Medicine, and the Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA

Abstract 

The treatment of localized esophageal cancer (LEC) is controversial. The approaches that are used in daily practice include surgery or radiation alone, preoperative or postoperative radiation, preoperative or postoperative chemotherapy, and definitive or preoperative chemoradiation. The varied modalities used to treat LEC reflect both the lack of randomized trial data and the suboptimal results with current therapy. Nonetheless, the available data suggest that surgery and definitive concurrent chemoradiation represent two standard treatment options. The use of preoperative chemoradiation remains investigational, with phase III trials failing to demonstrate a consistent benefit for this option over chemoradiation or surgery alone. This review will examine the available data on the current treatment approaches in LEC.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(04)00236-2

doi:10.1053/j.seminoncol.2004.04.015

Seminars in Oncology
Volume 31, Issue 4 , Pages 554-565, August 2004